使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2026 conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
各位好,感謝您撥冗等候。歡迎參加 Heron Therapeutics 2026 年第一季電話會議。(接線員指示) 請注意,今天的會議將被錄音。
I would now like to hand the conference over to your first speaker today, Melissa Jarel, Vice President of Legal. You may begin.
現在我想把會議交給今天的第一位講者,法務副總裁 Melissa Jarel。您可以開始了。
Melissa Jarel - Vice President of Legal
Melissa Jarel - Vice President of Legal
Thank you, operator, and hello, everyone. Thank you for joining us on the Heron Therapeutics conference call today to discuss the company's financial results for the first-quarter 2026. With me today from Heron are Craig Collard, Chief Executive Officer; Ira Duarte, Executive Vice President and Chief Financial Officer; Bill Forbes, Executive Vice President and Chief Development Officer; Mark Hensley, Chief Operating Officer; and Kevin Warner, Senior Vice President, Medical Affairs, Strategy and Engagement. For those of you participating via conference call, slides are made available via webcast and can also be accessed via the Investor Relations page of our website following the conclusion of today's call.
謝謝,接線員,大家好。感謝各位今天參加 Heron Therapeutics 的電話會議,討論公司 2026 年第一季的財務結果。今天與我一同出席的 Heron 團隊成員包括:執行長 Craig Collard;執行副總裁兼財務長 Ira Duarte;執行副總裁兼開發長 Bill Forbes;營運長 Mark Hensley;以及醫療事務、策略與互動資深副總裁 Kevin Warner。對於透過電話會議參與的各位,簡報投影片已透過網路直播提供,並且在今日電話會議結束後,也可於我們網站的投資人關係頁面存取。
Before we begin, let me quickly remind you that during the course of this conference call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs, and future performance, all of which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. These statements are based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
在開始之前,我先快速提醒各位:在本次電話會議過程中,公司將作出前瞻性陳述。我們提醒您,任何非歷史事實的陳述皆屬前瞻性陳述。其中包括關於公司預測、預期、計畫、信念與未來表現的評論;就 1995 年《私人證券訴訟改革法》(Private Securities Litigation Reform Act of 1995) 的「安全港」條款而言,以上皆構成前瞻性陳述。這些陳述係基於本次電話會議當日的判斷與分析,並受多項重要風險與不確定性影響,可能導致實際結果與前瞻性陳述所描述者出現重大差異。
The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the Safe Harbor statement in today's press release and in Heron's public periodic filings with the SEC. Except as required by law, Heron assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so.
本次電話會議與網路直播中所作前瞻性陳述相關的風險與不確定性,已載於今日新聞稿中的安全港聲明,以及 Heron 向美國證券交易委員會(SEC)提交的公開定期申報文件中。除法律要求外,Heron 不承擔更新這些前瞻性陳述以反映未來事件或實際結果之義務,且無意如此。
And with that, I would now like to turn the call over to Craig Collard, Chief Executive Officer of Heron.
接下來,我想把電話會議交給 Heron 的執行長 Craig Collard。
Craig Collard - Chief Executive Officer, Director
Craig Collard - Chief Executive Officer, Director
Thanks, Melissa. Hello, everyone, and welcome to Heron Therapeutics first-quarter 2026 earnings call. Today, we're thrilled to share our financial results and provide commercial updates on our business. I'd like to begin by highlighting several key accomplishments.
謝謝你,Melissa。各位好,歡迎參加 Heron Therapeutics 2026 年第一季財報電話會議。今天我們很高興與各位分享財務結果,並提供業務的商業化最新進展。我想先強調幾項關鍵成果。
Coming off a strong fourth quarter of 2025, we entered the new year with tremendous momentum. As expected, the first quarter of any year historically brings seasonal headwinds driven by co-pay resets and insurance adjustments, and this year was no exception.
在 2025 年第四季表現強勁之後,我們帶著十足動能進入新的一年。如同預期,每年的第一季在歷史上通常會因自付額(co-pay)重置與保險調整而面臨季節性逆風,今年也不例外。
However, 2026 presented additional challenge for us, 2 weeks of severe weather early in the quarter that significantly compounded the typical seasonal softness, making January our most difficult month since I joined the company. The impact of the weather was felt most acutely in elective surgeries, which are highly sensitive to extreme conditions and saw a sharp decline during that period.
然而,2026 年對我們而言還出現了額外挑戰:本季初有兩週的嚴重天候,顯著加劇了典型的季節性疲弱,使得一月成為自我加入公司以來最艱難的一個月。天候影響在選擇性手術上最為明顯;此類手術對極端狀況高度敏感,並在該期間出現明顯下滑。
Importantly, this was not an isolated experience. Multiple publicly traded pharmaceutical and surgical companies have reported the same weather-driven disruption across January and February. The breadth of this industry-wide impact validates that the headwinds we faced were external and temporary in nature, not reflective of any underlying weakness in our business or markets.
重要的是,這並非孤立事件。多家上市的製藥與外科相關公司都回報在一月與二月出現同樣由天候驅動的干擾。此一影響在整個產業的廣泛性,證實我們面臨的逆風屬於外部且暫時性的因素,並不反映我們業務或市場的任何基本面疲弱。
Despite this, the team responded well. February brought a clear upward trend and March closed strongly with over $15 million in net sales, demonstrating the underlying strength and resilience of the business.
儘管如此,團隊的應對表現良好。二月呈現明確的回升趨勢,三月則強勢收官,淨銷售額超過 1,500 萬美元,展現出業務的內在實力與韌性。
While the weather undoubtedly weighed on our Q1 results, it has not shaken our confidence in the year ahead. We fully expect the remaining deferred elective procedures to be rescheduled throughout the remainder of 2026, creating a meaningful tailwind as we progress through the year. This aligns with our historical pattern where Q3 and Q4 consistently represent our highest volume quarters, and we anticipate 2026 will be no different.
雖然天候無疑拖累了我們第一季的結果,但並未動搖我們對未來一年的信心。我們完全預期其餘被延後的選擇性手術將在 2026 年剩餘期間陸續重新排程,隨著年度推進形成具意義的順風。這也符合我們的歷史模式:第三季與第四季一向是我們量能最高的季度,我們預期 2026 年亦不例外。
Turning to our Acute Care portfolio, we delivered revenue growth of 32% compared to the same period last year, with ZYNRELEF growing 27% and APONVIE growing over 50%, respectively. Two structural drivers are worth highlighting. Our IGNITE program, the incentive program with our orthopedic distribution partners has been very successful, and we're continuing it into 2026 as a key growth driver for ZYNRELEF. With APONVIE, we are beginning to realize the commercial benefits of its inclusion in the fifth consensus guidelines for the management of postoperative nausea and vomiting, a meaningful clinical endorsement that we believe will serve as a sustained tailwind for adoption. We will provide additional detail later in the presentation on the strategic and commercial implications of that inclusion.
談到我們的急性照護(Acute Care)產品組合,與去年同期相比,我們實現 32% 的營收成長,其中 ZYNRELEF 成長 27%,APONVIE 成長超過 50%。有兩項結構性驅動因素值得強調。我們的 IGNITE 計畫——與骨科通路合作夥伴的獎勵計畫——成效非常顯著,我們將在 2026 年持續推動,作為 ZYNRELEF 的關鍵成長動能。就 APONVIE 而言,我們開始實現其納入第五版術後噁心與嘔吐(PONV)管理共識指引所帶來的商業效益;這是一項重要的臨床背書,我們相信將成為推動採用的持續性順風。稍後在簡報中,我們將就該納入所帶來的策略與商業意涵提供更多細節。
Turning to our sales force expansion, implementation is on track for the third quarter with the recruitment already underway. We view this as a significant catalyst for growth across our portfolio, and we will walk through the strategy in more detail in the presentation.
接著談到我們的銷售團隊擴編,相關導入進度符合第三季的時程,招募工作已在進行中。我們視此為推動整體產品組合成長的重要催化劑,並將在簡報中更詳細說明策略。
Moving on to oncology, we continue to deliver solid performance with CINVANTI despite increased competitive pressure. For the quarter, CINVANTI maintained exit market share of 25% in the NK1 category. And although net sales reflected normal quarter-to-quarter timing, CINVANTI itself has remained resilient, demonstrating strong customer loyalty and continued demand even in this very competitive landscape. We have a number of new accounts coming on board in Q2 that we anticipate could add upwards of $10 million in net revenue on an annualized basis.
再來談腫瘤領域,儘管競爭壓力加大,我們的 CINVANTI 仍持續展現穩健表現。本季 CINVANTI 在 NK1 類別的期末(exit)市占率維持在 25%。此外,雖然淨銷售額反映了正常的季度間時點差異,CINVANTI 本身仍保持韌性,展現出強勁的客戶忠誠度與持續需求,即使在競爭非常激烈的環境中亦然。我們在第二季將有多個新客戶導入,我們預期按年化基礎計算,可能帶來超過 1,000 萬美元的淨營收增量。
We will cover this in greater detail as part of the commercial performance update. Before I turn things over to Mark to cover our commercial performance, I want to take a moment again to recognize the entire Heron team for their performance this quarter. We fight every day in a very competitive environment, and this quarter offered other challenges that we had no control over, yet our team continues to persevere and move forward.
我們將在商業表現更新中更深入說明。在我把時間交給 Mark 介紹商業表現之前,我想再次花點時間肯定整個 Heron 團隊在本季的表現。我們每天都在高度競爭的環境中奮戰,而本季也出現了其他我們無法控制的挑戰;即便如此,我們的團隊仍持續堅持並向前推進。
I will now turn the call over to Mark to cover our commercial performance. Go ahead, Mark.
現在我把電話會議交給 Mark,請他說明我們的商業表現。Mark,請。
Mark Hensley - Chief Operating Officer, Executive Vice President
Mark Hensley - Chief Operating Officer, Executive Vice President
Thanks, Craig. Moving to product performance, starting with our overall net sales picture for the quarter, this chart shows quarterly net revenue for each product across the last 4 quarters. Total net sales of $34.7 million in Q1. On the Acute Care side, $13.6 million combined: ZYNRELEF at $10.2 million, APONVIE at $3.4 million; on the oncology side, $21.1 million combined: CINVANTI at $20.5 million, SUSTOL at $0.6 million, reflecting the planned wind down we previously discussed.
謝謝,Craig。接著看產品表現,先從本季整體淨銷售概況開始;此圖表顯示過去 4 個季度各產品的季度淨營收。第一季淨銷售總額為 3,470 萬美元。在急性照護方面,合計 1,360 萬美元:ZYNRELEF 為 1,020 萬美元,APONVIE 為 340 萬美元;在腫瘤方面,合計 2,110 萬美元:CINVANTI 為 2,050 萬美元,SUSTOL 為 60 萬美元,反映我們先前討論過的計畫性逐步縮減(wind down)。
You can see the sequential dynamics on each product. A few of these reflect ordering and channel patterns rather than changes in underlying demand. The cleaner read on adoption across all four products is the demand unit and ordering account data, which I'll cover in detail as we go. But before we get into individual product performance, there's an important strategic point on the next slide.
您可以看到各產品的連續性動態。其中有幾項反映的是訂購與通路模式,而非基礎需求的變化。要更乾淨地判讀四項產品的採用情況,應看需求單位與下單帳戶數據;我會在後續逐一詳細說明。但在進入各產品的個別表現之前,下一張投影片有一個重要的策略重點。
This slide shows our net selling price per unit across the four products over the last four quarters. The Y-axis values aren't displayed. What matters is the directional trend within each product. Starting with ZYNRELEF, net selling price has been steadily increasing across the period. Our pricing posture is holding and the J-code and NOPAIN environment are supporting that trajectory.
這張投影片顯示我們四項產品在過去四個季度的每單位淨售價。Y 軸數值未顯示。重點在於各產品內部的趨勢方向。先看 ZYNRELEF,淨售價在此期間持續穩步上升。我們的定價立場維持穩健,而 J-code 與 NOPAIN 的環境也在支撐這一走勢。
For APONVIE, net price has been stable. That's what we'd expect for a product still in its growth phase, where our focus is volume penetration rather than per unit price extraction. On CINVANTI, you'll notice the Q4 bar is slightly lower than the surrounding quarters with Q1 returning to a level consistent with our strategy. That Q4 dynamic was temporary and Q1 reflected normal channel ordering patterns following the Q4 activity. The more important point, our underlying pricing strategy on CINVANTI is intact and disciplined and SUSTOL declining in line with planned wind down.
對 APONVIE 而言,淨價格保持穩定。這符合我們對仍處於成長期產品的預期:重點在於滲透量,而非每單位價格的極大化。至於 CINVANTI,您會注意到 Q4 的柱狀略低於前後季度,而 Q1 又回到與我們策略一致的水準。Q4 的動態是暫時性的,Q1 則反映了在 Q4 活動之後正常的通路訂購模式。更重要的是,我們在 CINVANTI 的基礎定價策略依然完整且嚴謹;而 SUSTOL 則如計畫般隨著逐步退場而下滑。
The headline message of this slide is straightforward. Across our active commercial products, we are maintaining pricing discipline and not chasing volume through price concessions. That's a deliberate strategic choice. It protects the long-term economics of the franchise and supports the durable recurring demand we're building.
這張投影片的重點訊息很直接。在我們仍在商業化的產品中,我們維持定價紀律,不會透過讓價來追求量。這是刻意的策略選擇。它能保護產品組合的長期經濟性,並支撐我們正在建立的、可持續的經常性需求。
Now on to ZYNRELEF, you can see the two charts on the slide, average daily units on the left, ordering accounts on the right. Both have continued to trend up through Q1. The number I'd anchor on is demand unit growth of 22% year-over-year. The broader local anesthetic market was down sequentially in Q1.
接著看 ZYNRELEF,投影片上有兩張圖:左邊是平均每日單位數,右邊是下單帳戶數。兩者在 Q1 都持續上升。我會特別強調的數字是需求單位年增 22%。更廣泛的局部麻醉藥市場在 Q1 的環比是下滑的。
In that environment, ZYNRELEF outgrew the market on a year-over-year basis and held share sequentially. The underlying franchise is performing. On reimbursement, the permanent J-code, J0668 has been live since October. Combined with the NOPAIN Act framework that took effect at the start of 2025, the reimbursement environment for ZYNRELEF is the cleanest it's been since launch. That framework streamlines reimbursement across approximately 110 million covered lives on the commercial side.
在那樣的環境下,ZYNRELEF 仍在年比基礎上跑贏市場,且在環比上維持市占。這個基礎產品線表現良好。在給付方面,永久 J-code(J0668)自 10 月起已正式啟用。再加上於 2025 年初生效的 NOPAIN 法案框架,ZYNRELEF 的給付環境是自上市以來最清晰的一次。該框架在商業保險端簡化了約 1.1 億受保人生命的給付流程。
Two quarters in, reimbursement conversations are smoother and the friction at the billing office level continues to come down. Looking at the Q2 through Q4 drivers on the right side of the slide, IGNITE has been extended throughout 2026 and expanded with IGNITE 2.0, which I'll cover on the next two slides. We're also seeing expansion of users within accounts, meaning more surgeons within each adopting institution moving on to ZYNRELEF as part of their protocol.
在推行兩個季度之後,給付相關的溝通更順暢,帳務辦公室層級的摩擦也持續下降。看投影片右側 Q2 到 Q4 的驅動因素,IGNITE 已延長至 2026 年並透過 IGNITE 2.0 擴大,我會在接下來兩張投影片說明。我們也看到帳戶內使用者擴張,也就是在每個採用機構中,有更多外科醫師將 ZYNRELEF 納入其標準流程。
And we'll be expanding our ZYNRELEF sales team in Q3 2026, targeted geographies where all three foundational drivers are fully in place: formulary access, the IGNITE program, and payer coverage. That expansion sits alongside the aprepitant team expansion, I'll cover on the APONVIE slide, reflecting our confidence in the trajectory of both franchises. On the longer-term side, our prefilled syringe presentation is in late-stage development. Bill will cover that in more detail later in the presentation.
我們也將在 2026 年 Q3 擴編 ZYNRELEF 銷售團隊,聚焦於三項基礎驅動因素都已完全到位的地區:處方集准入、IGNITE 計畫,以及保險給付覆蓋。這項擴編將與 aprepitant 團隊的擴編並行;我會在 APONVIE 的投影片中說明,這反映我們對兩個產品線走勢的信心。就長期而言,我們的預充式注射器劑型已進入後期開發。Bill 會在稍後的簡報中更詳細說明。
Moving on to Slide 10. Here is the data behind IGNITE 1.0. The chart shows ZYNRELEF unit volume across our IGNITE targeted accounts, pre-IGNITE versus post-IGNITE. We went from approximately 9,000 units in the last pre-IGNITE quarter of last year to over 19,000 units by Q4 of last year. That's 111% growth within these targeted accounts in just two quarters of the program. This is the data that gave us the conviction to extend IGNITE through 2026 and expand it further.
接著看第 10 張投影片。這裡是 IGNITE 1.0 背後的數據。圖表顯示在我們 IGNITE 鎖定的帳戶中,ZYNRELEF 的單位量在 IGNITE 前與 IGNITE 後的對比。我們從去年最後一個 IGNITE 前季度約 9,000 單位,提升到去年 Q4 超過 19,000 單位。也就是在該計畫僅兩個季度內,這些目標帳戶的成長達 111%。正是這些數據讓我們有信心將 IGNITE 延長至 2026 年並進一步擴大。
On slide 11, you can see what IGNITE 2.0 looks like. IGNITE 1.0 in the second half of 2025 covered 2,261 accounts. IGNITE 2.0, which is now live for full year '26, covers 3,109 accounts. That's a 38% increase, adding 848 additional accounts to the program. More accounts in the program means more concentrated distributor focus on the institutions we've identified as most likely to adopt and deepen ZYNRELEF use. The structural drivers that produced 111% unit growth in IGNITE 1.0 are now applied to a meaningfully larger base of accounts in 2026.
在第 11 張投影片,您可以看到 IGNITE 2.0 的樣貌。2025 年下半年,IGNITE 1.0 覆蓋 2,261 個帳戶。IGNITE 2.0 現已於 2026 全年上線,覆蓋 3,109 個帳戶。這是 38% 的增加,為計畫新增 848 個帳戶。計畫涵蓋更多帳戶,意味著經銷商能更集中地聚焦於我們所辨識、最可能採用並深化 ZYNRELEF 使用的機構。在 IGNITE 1.0 促成 111% 單位成長的結構性驅動因素,將於 2026 年套用到顯著更大的帳戶基礎上。
I will now turn it over to Bill to cover the prefilled syringe.
接下來我把時間交給 Bill,說明預充式注射器。
William Forbes - Executive Vice President, Chief Development Officer
William Forbes - Executive Vice President, Chief Development Officer
Thank you, Mark. This slide highlights the strong momentum in our Acute Care franchise and the continued advancement of the ZYNRELEF prefilled syringe program. We have seen consistent and accelerating adoption across our device preparation platforms as we transition from the vented vial spike or VVS to the significantly improved vile access needle or VAN. This evolution has been well received and reflects clear progress in ease of use and workflow efficiency.
謝謝你,Mark。這張投影片突顯我們急性照護(Acute Care)產品線的強勁動能,以及 ZYNRELEF 預充式注射器計畫的持續推進。隨著我們從帶通氣瓶刺(vented vial spike,VVS)轉換到大幅改良的瓶口取用針(vial access needle,VAN),我們在各項器械準備平台上看到一致且加速的採用。這項演進獲得良好回饋,清楚反映在易用性與工作流程效率上的進步。
At the same time, market demand continues to shift toward ready-to-use systems, which are emerging as an important growth driver as hospitals prioritize efficiency, safety and streamlined operating room workflows. Independent third-party forecasts reinforce the durability of this trend with prefilled syringe adoption expected to scale meaningfully over time. From a program standpoint, the ZYNRELEF PFS is fully funded and on track.
同時,市場需求持續轉向即用型(ready-to-use)系統;隨著醫院將效率、安全與手術室流程簡化列為優先事項,這正成為重要的成長驅動因素。獨立第三方預測也強化了此趨勢的持久性,預期預充式注射器的採用將隨時間顯著擴大。就計畫而言,ZYNRELEF PFS 已獲全額資金支持並按計畫推進。
It was designed to align with contemporary health system expectations, including both ASHP and Joint Commission guidance, while improving operating room workflow, reducing preparation steps and lowering the risk of medication errors and contamination. The development program is well advanced. Registration batches have been manufactured and placed on stability, and we remain on track to generate 12-month stability data in the first quarter of 2027.
其設計旨在符合當代醫療體系的期待,包括 ASHP 與 Joint Commission 的指引,同時改善手術室工作流程、減少配製步驟,並降低用藥錯誤與污染風險。開發計畫已相當成熟。註冊批次已完成製造並進入穩定性試驗,我們仍按計畫在 2027 年第一季取得 12 個月穩定性數據。
Mark, I'll turn it back to you.
Mark,我把時間交回給你。
Mark Hensley - Chief Operating Officer, Executive Vice President
Mark Hensley - Chief Operating Officer, Executive Vice President
Thanks, Bill. Now to APONVIE. There are two charts on this slide, average daily units on the left, ordering accounts on the right. Both showed continued steady upward trajectory through Q1.
謝謝,Bill。接著看 APONVIE。這張投影片有兩張圖:左邊是平均每日單位數,右邊是下單帳戶數。兩者在 Q1 都呈現持續且穩健的上升趨勢。
On the Q1 metrics, APONVIE demand units grew 68% year over year. Average daily units grew 70% over Q1 of last year. We exited Q1 with 371 ordering accounts in March. That's an all-time high for the product and up 67% versus March of last year. And APONVIE is now P&T approved in 1,903 accounts, representing 5.8 million medium to high-risk procedures annually. The last number defines the size of the addressable opportunity that APONVIE has now been formally cleared into.
就 Q1 指標而言,APONVIE 的需求單位年增 68%。平均每日單位數較去年 Q1 成長 70%。我們在 3 月以 371 個下單帳戶結束 Q1。這是該產品的歷史新高,較去年 3 月增加 67%。此外,APONVIE 目前已在 1,903 個帳戶獲 P&T 核准,代表每年 580 萬件中至高風險手術。最後這個數字界定了 APONVIE 目前已正式獲准進入的可觸及機會規模。
On the growth drivers ahead, APONVIE's permanent product-specific J-code became active April 1, having a permanent dedicated billing code in place removes a layer of reimbursement complexity for the product. We'll be expanding our dedicated aprepitant sales force in Q3 2026. That team currently covers both APONVIE and CINVANTI and the expansion adds capacity to support both products.
關於未來的成長驅動因素,APONVIE 針對永久性產品專屬的 J-code 已於 4 月 1 日生效;建立永久且專用的計費代碼,可為該產品移除一層報銷複雜性。我們將在 2026 年第三季擴編專屬的 aprepitant 銷售團隊。該團隊目前同時涵蓋 APONVIE 與 CINVANTI,而此次擴編將增加產能以支援兩項產品。
And lastly, APONVIE has been prominently included in the fifth consensus guidelines for the management of postoperative nausea and vomiting. That's a meaningful clinical catalyst. I'll hand it over to Kevin to walk through the guidelines and what they mean for the product.
最後,APONVIE 已被顯著納入第五版術後噁心與嘔吐管理共識指引。這是一項具重要意義的臨床催化因素。我將把時間交給 Kevin,請他帶大家了解這些指引以及其對產品的意義。
Kevin Warner - Senior Vice President, Medical Affairs, Strategy and Engagement.
Kevin Warner - Senior Vice President, Medical Affairs, Strategy and Engagement.
Thanks, Mark. We wanted to provide a brief overview to help the Street understand the broader clinical and economic significance of the recently published fifth consensus guidelines for the management of postoperative nausea and vomiting. These guidelines represent an important shift in perioperative care, moving from reactive management of PONV toward a far more proactive patient-centered prevention strategy.
謝謝你,Mark。我們想做一個簡要概述,協助華爾街理解近期發布的第五版術後噁心與嘔吐管理共識指引在更廣泛的臨床與經濟層面的重要性。這些指引代表圍手術期照護的一項重要轉變,從對 PONV 的反應式處置,轉向更為主動、以病人為中心的預防策略。
From a medical affairs perspective, guideline updates are highly important because they often serve as the foundation for durable institutional change. Historically, adoption occurs over time through provider education, EMR order sets, anesthesia workflows, perioperative pathways and treatment algorithms.
從醫學事務的角度來看,指引更新非常重要,因為它們往往是促成長期機構性變革的基礎。歷史上,採用通常會隨時間推進,透過醫療提供者教育、EMR 醫囑套組、麻醉工作流程、圍手術期照護路徑與治療演算法逐步落地。
Once integrated into institutional protocols, these practices tend to become highly durable standards of care. Importantly, the updated guidelines substantially elevated the role of NK1 antagonist within multimodal prophylaxis strategies. Aprepitant-based therapies, including APONVIE, received an A1 evidence rating for prevention of PONV in adults, reflecting the highest level of evidence supporting efficacy and safety.
一旦納入機構的標準作業流程,這些做法往往會成為高度持久的照護標準。重要的是,更新後的指引在多模式預防策略中大幅提升了 NK1 拮抗劑的角色。以 aprepitant 為基礎的治療(包括 APONVIE)在成人 PONV 預防方面獲得 A1 證據等級評定,反映支持其療效與安全性的最高等級證據。
APONVIE is specifically named within the guidelines as the first and only FDA-approved IV push NK1 antagonist for the prevention of PONV in adults. We believe this distinction is clinically meaningful because it combines efficacy, workflow efficiency and ease of perioperative implementation in a way that supports both providers and patients.
指引中特別點名 APONVIE,為成人 PONV 預防領域第一且唯一獲 FDA 核准的靜脈推注(IV push)NK1 拮抗劑。我們認為這項差異在臨床上具有重要意義,因為它以能同時支持醫護人員與病人的方式,結合了療效、工作流程效率與圍手術期導入的便利性。
Another key evolution within the guidelines is the broader recommendation for multimodal prophylaxis. While patient and procedure-specific risk stratification remains central, the updated guidance recognizes that the benefit of prophylaxis often outweighs the risk of undertreatment. As a result, many institutions are expected to adopt a more liberal prophylaxis strategy across broader patient populations.
指引中的另一項關鍵演進,是更廣泛地建議採用多模式預防。雖然以病人與手術類型為基礎的風險分層仍是核心,但更新後的建議也認知到,預防的效益往往大於治療不足的風險。因此,預期許多機構將在更廣泛的病人族群中採用更寬鬆的預防策略。
The guidelines specifically recommend that patients with greater than two risk factors, representing roughly half of the surgical population received three to four prophylactic interventions. These medium and high-risk patients often require highly effective antiemetic strategies without adding recovery-limiting adverse effects.
指引特別建議,具有超過兩項風險因子的病人(約占手術族群的一半)應接受三到四項預防性介入。這些中度與高度風險病人往往需要高效的止吐策略,同時避免增加限制復原的不良反應。
We believe APONVIE is uniquely positioned in this setting. Its efficacy profile, combined with a differentiated safety profile that does not overlap with many commonly used antiemetics supports use in patients where prevention matters most. Importantly, APONVIE provides antiemetic protection without contributing to sedation or negatively impacting postoperative recovery pathways, which is increasingly important in enhanced recovery protocols and ambulatory surgery.
我們認為 APONVIE 在此情境下具備獨特優勢。其療效表現,加上與許多常用止吐藥不重疊的差異化安全性特徵,支持其用於最需要預防的病人。重要的是,APONVIE 可提供止吐保護而不造成鎮靜,也不會對術後復原路徑產生負面影響;在加速康復(enhanced recovery)方案與門診手術日益重要的趨勢下,這點愈發關鍵。
One of the most significant additions to the Fifth Edition guidelines was the expanded focus on post-discharge nausea and vomiting, or PDNV. The guidelines emphasize that PONV is not simply an acute PACU complication. For many patients, symptoms occur after discharge when clinical support resources are less available. The guidelines cite data showing approximately 37% of patients may experience PDNV with implications for dehydration, wound complications, unplanned health care utilization and potential readmissions. As outpatient surgery volumes continue to expand and same-day discharge becomes increasingly common, these downstream complications become even more relevant in value-based care models.
第五版指引中最重要的新增內容之一,是擴大聚焦於出院後噁心與嘔吐(PDNV)。指引強調,PONV 不僅僅是麻醉後恢復室(PACU)的急性併發症。對許多病人而言,症狀會在出院後出現,而此時可獲得的臨床支援資源較少。指引引用資料顯示,約 37% 的病人可能經歷 PDNV,並可能導致脫水、傷口併發症、非計畫性醫療利用以及潛在再入院。隨著門診手術量持續擴大、當日出院愈來愈常見,這些下游併發症在以價值為導向的照護模式中變得更為相關。
Importantly, the guidelines now recommend that patients at risk for PDNV receive prophylactic long-acting antiemetics prior to discharge. We believe APONVIE aligns well with this recommendation given its 48-hour duration of action and ability to provide extended receptor coverage during the vulnerable post-discharge period. The guidelines also reinforce several important differentiators associated with APONVIE and MK1 antagonist therapy more broadly.
重要的是,指引現在建議,具有 PDNV 風險的病人在出院前應接受預防性的長效止吐藥。我們認為 APONVIE 與此建議高度契合,因其作用可持續 48 小時,並能在出院後的脆弱期提供延長的受體覆蓋。指引也再次強調了與 APONVIE 以及更廣泛的 NK1 拮抗劑治療相關的幾項重要差異化特點。
APONVIE is administered as a simple 30-second IV push with rapid onset and greater than or equal to 97% receptor occupancy within 5 minutes, integrating efficiently into standard anesthesia workflows. This becomes particularly relevant for providers who may not have had adequate preoperative time or oral administration or who are caring for patients with limitations to oral therapies, including those with gastroparesis, GLP-1 utilization, diabetes-related GI dysfunction or altered gastric emptying.
APONVIE 以簡單的 30 秒靜脈推注給藥,起效迅速,且在 5 分鐘內受體佔有率可達大於或等於 97%,可高效率地整合進標準麻醉工作流程。這對於可能沒有足夠術前時間進行口服給藥的醫護人員,或照護口服治療受限病人的情境尤其重要;此類限制包括胃輕癱、使用 GLP-1、糖尿病相關腸胃功能障礙或胃排空改變等。
The strength of evidence supporting aprepitant-based therapy was also highlighted throughout the guidelines multiple randomized trials demonstrated aprepitant to be comparable or superior to ondansetron for prevention of PONV. Meta-analysis showed significant reductions in PONV risk when used alone or within multimodal regimens. And a large Cochrane systemic review evaluating nearly 100,000 patients ranked aprepitant as the single most effective antiemetic.
指引亦在多處強調支持 aprepitant 為基礎治療的證據力:多項隨機試驗顯示,aprepitant 在 PONV 預防方面與 ondansetron 相當或更優。統合分析顯示,無論單獨使用或納入多模式方案,均可顯著降低 PONV 風險。此外,一項評估近 10 萬名病人的大型 Cochrane 系統性回顧將 aprepitant 排名為單一最有效的止吐藥。
Importantly, the updated guidelines frame PONV prevention not simply as a patient comfort initiative, but as a meaningful clinical quality and operational issue. Poorly controlled PONV contributes to extended PACU stays, rescue medication use, delayed discharge, dehydration, wound stress, aspiration concerns and readmissions. In many high-risk procedures, including abdominal bariatric, ENT, ophthalmology and other belt-up surgeries, preventing vomiting is viewed as critically important to protecting surgical outcomes and patient safety.
重要的是,更新後的指引將 PONV 預防定位為不僅是提升病人舒適度的措施,而是一項具有實質意義的臨床品質與營運議題。PONV 控制不佳會導致 PACU 停留時間延長、使用救援藥物、出院延遲、脫水、傷口張力增加、誤吸疑慮以及再入院。在許多高風險手術中,包括腹部減重手術、耳鼻喉科、眼科及其他腰部以上手術,預防嘔吐被視為對保護手術結果與病人安全至關重要。
Appropriate prophylaxis also supports perioperative operational efficiency by reducing nursing burden, minimizing recovery delays, improving throughput and enhancing both patient and staff satisfaction. The guidelines additionally highlighted the pharmacoeconomic value of effective prophylaxis strategies. One metric discussed was number needed to treat or NNT. For aprepitant combined with dexamethasone, the reported NNT was 3.8, meaning approximately four patients treated prevents one additional case of PONV. Compared with many commonly used antiemetics, this represents a highly favorable value proposition.
適當的預防也能透過降低護理負擔、減少復原延遲、提升周轉率,並增進病人與員工滿意度,來支持圍手術期的營運效率。指引亦強調有效預防策略的藥物經濟學價值。其中一項討論的指標是治療必要人數(number needed to treat,NNT)。對於 aprepitant 合併 dexamethasone,報告的 NNT 為 3.8,意即約治療四位病人即可額外預防一例 PONV。相較於許多常用止吐藥,這代表非常有利的價值主張。
From a health system perspective, this becomes clinically and economically meaningful very quickly. A single episode of PONV has been estimated to cost approximately $1,000 when considering rescue therapy, nursing utilization, prolonged PACU time and delayed discharge.
從醫療體系角度來看,這很快就會在臨床與經濟層面產生顯著意義。在考量救援治療、護理資源使用、PACU 時間延長與出院延遲後,單次 PONV 事件的成本估計約為 1,000 美元。
When viewed in that context, preventing complications with an intervention costing approximately $60 per dose becomes highly rational and understandable for providers and institutions alike, particularly as value-based care models increasingly focus on patient satisfaction, throughput, readmissions, recovery quality and total episode of care costs. Ultimately, we believe the fifth consensus guidelines reinforce several important macro trends shaping the perioperative landscape, including greater use of multimodal prophylaxis, increasing recognition of post-discharge nausea vomiting, continued migration toward outpatient surgery, demand for workflow efficiency and the growing need for safe, effective nonsedating long-acting therapies that support enhanced recovery pathways, which we believe APONVIE is uniquely positioned to address.
在此背景下,以每劑約 60 美元的介入來預防併發症,對醫護人員與機構而言就顯得非常合理且易於理解,尤其是在以價值為導向的照護模式日益聚焦於病人滿意度、周轉率、再入院、復原品質與整體照護事件成本之際。最終,我們認為第五版共識指引強化了幾項正在塑造圍手術期環境的重要宏觀趨勢,包括更廣泛採用多模式預防、對出院後噁心嘔吐的認知提升、持續向門診手術遷移、對工作流程效率的需求,以及對安全、有效、非鎮靜且長效治療以支持加速康復路徑的日益需求;我們相信 APONVIE 具備獨特定位可因應這些需求。
I will now turn the call back to Mark to discuss our oncology supportive care franchise.
我現在把電話交回給 Mark,請他討論我們的腫瘤支持性照護產品線。
Mark Hensley - Chief Operating Officer, Executive Vice President
Mark Hensley - Chief Operating Officer, Executive Vice President
Thanks, Kevin. Turning to oncology supportive care, there are two charts on this slide, average daily units on the left, ordering accounts on the right. CINVANTI's average daily units have remained resilient, sustaining a consistent trend in utilization throughout 2024 and into 2026. That's a meaningful durability marker for a product in its mature commercial phase in a category that has faced steady competitive pressure.
謝謝你,Kevin。接著談腫瘤支持性照護,這張投影片上有兩張圖:左邊是平均每日使用單位數,右邊是下單帳戶數。CINVANTI 的平均每日使用單位數一直保持韌性,於 2024 年並延續至 2026 年,使用量趨勢維持一致。對於一個處於成熟商業化階段、且所在類別長期面臨競爭壓力的產品而言,這是重要的耐久性指標。
On ordering accounts, you can see the two layers on the right chart. The blue line shows existing accounts running at approximately 1,100 every month, which speaks to the stickiness of the customer base. The purple line shows new and returning accounts averaging about 59 per month in Q1 of '26. In March specifically, 1,188 accounts ordered CINVANTI. That number was in line with the 12-month average of approximately 1,200 accounts.
在下單帳戶方面,你可以看到右側圖表的兩個層次。藍線顯示既有帳戶每月約維持在 1,100 個左右,這反映了客戶基礎的黏著度。紫線顯示新進與回流帳戶在 2026 年第一季平均每月約 59 個。以 3 月為例,共有 1,188 個帳戶下單購買 CINVANTI。這個數字與過去 12 個月約 1,200 個帳戶的平均值一致。
On market share, CINVANTI ended Q1 with 25% exit share in March of 2026. That was also in line with the 12-month average. The stability is the takeaway. We are holding our position in a competitive category. Looking at growth drivers for the rest of 2026, Greg referenced a number of new accounts coming online this year.
在市占率方面,CINVANTI 於 2026 年第一季結束時,3 月的期末市占率為 25%。這也與過去 12 個月的平均值一致。重點在於穩定性。我們在競爭激烈的類別中守住了既有位置。展望 2026 年剩餘期間的成長動能,Greg 提到今年將有多個新帳戶上線。
Those new formulary wins are due to our REIGNITE program. It's focused on CINVANTI access to major teaching hospitals, where we have already secured formulary wins and the near-term pipeline represents approximately $10 million in new opportunity. And as I mentioned earlier, our dedicated aprepitant sales force expansion in the third quarter of 2026 will support CINVANTI as well as APONVIE. CINVANTI will be promoted in the second position by that team.
這些新的處方集(formulary)納入成果來自我們的 REIGNITE 計畫。該計畫聚焦於讓 CINVANTI 進入主要教學醫院;我們已取得處方集納入,且短期管線約代表 1,000 萬美元的新機會。此外,如我先前提到的,我們將於 2026 年第三季擴編專責 aprepitant 的銷售團隊,這將同時支援 CINVANTI 與 APONVIE。該團隊將以第二順位推廣 CINVANTI。
Now to the broader category dynamics, on the next slide, the chart shows the broader NK1 category for chemotherapy-induced nausea and vomiting over the last 12 months. The stacked bars show total category units broken out by competitor product. The percentages at the top of each bar show month-over-month volatility in the overall category, ranging from down 19% in some months to up 21% in others. The line running across the chart is CINVANTI's market share within that category.
接著談更廣泛的類別動態,在下一張投影片中,圖表顯示過去 12 個月化療誘發噁心嘔吐(CINV)之 NK1 類別的整體情況。堆疊長條顯示該類別總使用單位數,並按競品拆分。每個長條上方的百分比顯示整體類別的月對月波動,某些月份下降 19%,另一些月份則上升 21%。橫跨圖表的折線則是 CINVANTI 在該類別中的市占率。
Despite all the category level volatility, CINVANTI's share has been remarkably stable. The 12-month average is 25%. March 2026 closed at 25%. That share stability in a category where the underlying volume is highly variable month-to-month is the durability marker for this franchise. To wrap up the commercial section, ZYNRELEF demand grew 22% year-over-year with IGNITE 2.0 expanding our targeted account base by 38% for 2026.
儘管類別層級波動很大,CINVANTI 的市占率卻異常穩定。12 個月平均為 25%。2026 年 3 月收在 25%。在基礎量能每月高度變動的類別中,這種市占穩定性就是此產品線的耐久性指標。最後總結商業面:在 IGNITE 2.0 的帶動下,ZYNRELEF 需求年增 22%,並使我們 2026 年的目標帳戶基礎擴大 38%。
APONVIE demand grew 68%. Ordering accounts hit an all-time high and the fifth consensus guidelines have positioned the product as the evidence-graded standard for PONV prophylaxis. CINVANTI held a stable 25% market share in a volatile category with reignite building approximately $10 million of near-term pipeline. Across all of it, our pricing discipline is intact. Our structural drivers are in place, and our commercial leverage continues to expand with both our ZYNRELEF team and our dedicated aprepitant team set to expand in Q3. The drivers we put in motion in '25 are working as designed, and we have line of sight to deliver on the full year framework we laid out in February.
APONVIE 需求成長 68%。下單帳戶數創歷史新高,而第五版共識指引已將該產品定位為 PONV 預防的、具證據分級的標準。CINVANTI 在波動的類別中維持穩定 25% 市占率,且 REIGNITE 正在建立約 1,000 萬美元的短期管線。在所有這些之中,我們的定價紀律依然完好。我們的結構性驅動因素已到位,且隨著 ZYNRELEF 團隊與專責 aprepitant 團隊都將於第三季擴編,我們的商業槓桿持續擴大。我們在 2025 年啟動的驅動因素正按設計發揮作用,我們也清楚可見能達成 2 月所提出的全年框架。
With that, I'll now turn it over to Ira.
接下來我把時間交給 Ira。
Ira Duarte - Chief Financial Officer, Executive Vice President
Ira Duarte - Chief Financial Officer, Executive Vice President
Thank you, Mark. As Craig noted, our financial results this quarter came in modestly below plan. That said, while winter storms are outside of our control, how we manage our business in response to them is not. And disciplined cost management remains a hallmark of this team that our shareholders have come to rely on. Net revenues for the quarter were $34.7 million, with gross margin coming in at 69%, below our typical low to mid-70s percent range.
謝謝你,Mark。如 Craig 所提到的,我們本季財務結果略低於計畫。話雖如此,冬季風暴不在我們可控範圍內,但我們如何因應並管理業務則是可控的。而嚴謹的成本管理仍是這個團隊的標誌,也是股東長期信賴我們的原因。本季淨營收為 3,470 萬美元,毛利率為 69%,低於我們通常約低至中 70% 的區間。
As we have discussed in prior calls, we have a secondary supplier for CINVANTI and carried a contractual obligation to produce a certain inventory quantities over the past year. That secondary product is manufactured in smaller batch sizes at roughly 3x the cost per batch of our primary supplier. This inventory will work its way through our system over the next two quarters, after which we will return exclusively to our primary supplier. Once those contractual obligations are fulfilled, we expect gross margins to normalize back to the mid-70% range.
如同我們在先前電話會議中討論過的,我們為 CINVANTI 設有第二供應商,且過去一年依合約負有生產一定庫存數量的義務。該第二來源產品以較小批量生產,每批成本約為主要供應商的 3 倍。這些庫存將在未來兩個季度逐步在我們的系統中消化,之後我們將恢復完全由主要供應商供貨。一旦合約義務履行完畢,我們預期毛利率將回復正常至約中 70% 的水準。
Adjusted EBITDA was negative $727,000 for the quarter, reflecting the combined impact of the storm-related revenue softness and the temporary gross margin pressure from our secondary CINVANTI supplier. Both factors are temporary, and we expect adjusted EBITDA to return to positive territory as we move through 2026. Looking ahead, the recovery is already underway. As noted earlier on the call, March net revenues returned to over $15 million, a strong signal for the second quarter and one that reinforces our confidence in achieving our full year targets. To reaffirm our 2026 guidance, we are maintaining net product sales of $173 million to $183 million and adjusted EBITDA of $10 million to $20 million, reflecting continued profitability alongside meaningful commercial expansion.
本季調整後 EBITDA 為負 72.7 萬美元,反映了風暴導致的營收疲弱,以及 CINVANTI 第二供應商帶來的暫時性毛利率壓力的綜合影響。這兩項因素皆為暫時性,我們預期隨著 2026 年推進,調整後 EBITDA 將回到正值。展望未來,復甦已在進行中。如先前在電話會議中提到,3 月淨營收已回升至超過 1,500 萬美元,這對第二季是強勁訊號,也強化我們達成全年目標的信心。為重申我們的 2026 年指引,我們維持產品淨銷售額 1.73 億至 1.83 億美元,以及調整後 EBITDA 1,000 萬至 2,000 萬美元,反映在持續獲利的同時推進具意義的商業擴張。
With that, we are happy to open the call for questions.
接下來,我們很高興開放提問。
Operator
Operator
(Operator Instructions) Brandon Folkes, H.C. Wainwright.
(接線員指示) Brandon Folkes,H.C. Wainwright。
Brandon Folkes - Equity Analyst
Brandon Folkes - Equity Analyst
Maybe just a few from me. Firstly, on your guidance, can you just talk about some of the pushes and pulls on ZYNRELEF that you assume to meet the overall company level revenue guidance? Do you assume ZYNRELEF taking market share? And then maybe secondly, apologies if I missed this. Can you just give me some details on the Baxter settlement, sort of what that allows, what that sort of keeps exclusivity?
我這邊可能幾個問題。首先,關於你們的財測指引,能否談談你們為了達成公司整體營收指引,在 ZYNRELEF 上假設有哪些推力與拉力因素?你們是否假設 ZYNRELEF 會提升市占率?第二個問題,如果我漏聽了先說抱歉。能否提供一些關於 Baxter 和解的細節,例如該和解允許什麼、以及在獨家性方面保留了哪些內容?
Yes, that's it for me. Maybe one more, just you talked about friction. So can you just talk about how you meaningfully change the adoption curve across ZYNRELEF and APONVIE. And on ZYNRELEF, it sounds like there's friction in sort of the office to decide to use ZYNRELEF. How do you change that ahead of the prefilled syringe and eliminate the friction you're seeing today so that the prefilled syringe can sort of maximize the value that it can bring?
好的,我這邊就這些。也許再一個,你們提到摩擦(friction)。能否談談你們如何實質改變 ZYNRELEF 與 APONVIE 的採用曲線。就 ZYNRELEF 而言,聽起來在診所端決定使用 ZYNRELEF 的流程上存在一些摩擦。在預充式注射器推出之前,你們要如何改變這點並消除目前看到的摩擦,讓預充式注射器能夠最大化其可帶來的價值?
Craig Collard - Chief Executive Officer, Director
Craig Collard - Chief Executive Officer, Director
Brandon, thank you for the questions. I'll start with the Baxter settlement, and then I'll turn it to Mark. Look, based on the terms of the settlement, we really can't go into the details of that other than to say that the dates and everything that have been published. But outside of that, we're just forbidden from saying anything on that. So I'll turn it over to Mark to talk about the ZYNRELEF questions that you asked.
Brandon,感謝你的提問。我先從 Baxter 和解案開始,接著我會交給 Mark。你看,依據和解條款,我們確實無法深入說明細節,只能說已公布的日期以及所有已對外發布的資訊。但除此之外,我們被禁止就此發表任何評論。所以我把時間交給 Mark,來回應你提出的 ZYNRELEF 相關問題。
Mark Hensley - Chief Operating Officer, Executive Vice President
Mark Hensley - Chief Operating Officer, Executive Vice President
Yes, it's a great question. I think one and three are part and parcel of the same. But in terms of our confidence, there are several factors that we're looking at. First, we talked about the weather and the elective procedures being pushed out of January. Obviously, we believe those will be rescheduled throughout the year.
是的,這是個很好的問題。我認為第一點和第三點其實是一體兩面。但就我們的信心而言,我們正在觀察幾個因素。首先,我們談到天氣因素以及選擇性手術被延後到一月之後。很明顯地,我們相信這些手術會在全年陸續重新排程。
And so certainly, that will be a nice tailwind for us. As it relates to both ZYNRELEF and APONVIE really, we're really focused on the expansion of the sales force in the kind of midyear. We certainly think that will help our share of voice and really kind of build upon the foundation that we've already built.
因此,這肯定會成為我們的一股順風。就 ZYNRELEF 與 APONVIE 而言,我們確實把重點放在年中左右擴編銷售團隊。我們當然認為這將有助於提升我們的聲量占比,並在我們已建立的基礎上進一步發展。
And then IGNITE 2.0, you see the slides and kind of what that delivered in the third and fourth quarter of last year. And so the expansion of that by 38% in 2026, we believe, will be a really nice tailwind for us as we go forward.
接著是 IGNITE 2.0,你們在投影片中也看到它在去年第三與第四季帶來的成果。因此,我們相信在 2026 年將其擴大 38%,會在我們未來推進時帶來非常好的順風。
And then on the friction piece, I think for us, we don't really see accounts that don't want to use ZYNRELEF. Really, the hardest part for us is getting to a meaningful enough number of them to have that kind of quarter-over-quarter growth that we would want to see with the product, right? And so a lot of that is the reason why we're expanding the team in the, kind of, midyear. And certainly, that share of voice will continue to grow. And so -- because we're continuing to see market share grow within our targeted accounts, certainly within the accounts where we're aligned, not only at Heron, but within our IGNITE program. And so we just want to continue to expand upon that across the country.
至於摩擦(friction)這一塊,我認為對我們來說,我們其實沒有看到不想使用 ZYNRELEF 的客戶。對我們而言最困難的是,如何接觸到足夠多、具有實質意義的客戶數量,才能讓產品達到我們希望看到的那種逐季成長,對吧?因此,這也是我們在年中左右擴編團隊的主要原因之一。而且,我們的聲量占比也會持續提升。因此——因為我們持續看到在目標客戶中的市占率成長,當然也包括我們已對齊的客戶,不僅是在 Heron 這邊,也在我們的 IGNITE 計畫中。所以我們希望在全國範圍內持續擴大這樣的成果。
Operator
Operator
Serge Belanger, Needham & Company.
Serge Belanger,Needham & Company。
Unidentified Participant
Unidentified Participant
This is John on for Serge today. First, if I could just follow up on ZYNRELEF again with regard to the 1Q winter storm headwinds, just curious if you could quantify the impact with regard to surgical volumes for the quarter there. And then second, on the implementation of NOPAIN. Obviously, it's been online for over a year now.
我是 John,今天代替 Serge。首先,如果可以的話,我想再追問一次 ZYNRELEF,關於第一季冬季風暴帶來的逆風,想請教你們是否能量化其對本季手術量的影響。第二個問題是關於 NOPAIN 的導入。很明顯地,它已經上線超過一年了。
Curious what impacts you're seeing on commercial coverage and how this has changed over time and what you might be expecting for '26? And then if I could just squeeze one more in on the CrossLink partnership. It seems like you're adding on to the initial IGNITE program, targeting more accounts here in '26. Curious if this is just throwing more muscle at the program to increase the accounts you're getting into and what else we might expect from this?
想了解你們在商業保險覆蓋方面看到哪些影響、這些影響隨時間如何變化,以及你們對 2026 年可能的預期是什麼?另外我再塞一個問題,關於與 CrossLink 的合作夥伴關係。看起來你們在 2026 年是在原本的 IGNITE 計畫基礎上加碼,鎖定更多客戶。想請教這是否只是對該計畫投入更多資源以增加你們能切入的客戶數,還是我們還能期待其他內容?
Mark Hensley - Chief Operating Officer, Executive Vice President
Mark Hensley - Chief Operating Officer, Executive Vice President
Great. Thank you for the questions. On surgical volume, our data shows this kind of high single-digit decline from the fourth quarter. So a pretty meaningful impact larger than we've seen in prior years. We think that's part weather-related, part a record Q4 from a surgical volume perspective and maybe some of our surgical partners just taking a deep breath in the quarter. But certainly, we expect that to significantly improve. And obviously, some of those surgeries that were lost, we would imagine that those would be rescheduled.
好的。感謝你的提問。關於手術量,我們的數據顯示相較第四季出現約高個位數的下滑。因此影響相當明顯,且比我們過去幾年看到的都更大。我們認為部分與天氣有關,部分是因為第四季手術量創下紀錄,另外也可能是我們的一些手術合作夥伴在本季稍作喘息。但我們確實預期這會顯著改善。而且很明顯地,那些流失的手術,我們推測會被重新排程。
To your second question on commercial coverage, we -- obviously, NOPAIN is a great factor for ZYNRELEF and certainly removes the word I've been using is friction, at least on the Medicare side, on the government payer side. And since its implementation, we've seen more and more commercial payers begin to add ZYNRELEF outside of the surgical bundles, reimbursing outside of that bundle. We reported the number on the call at 110 million lives is the estimate that we have on the commercial side.
至於你第二個關於商業保險覆蓋的問題——很明顯地,NOPAIN 對 ZYNRELEF 是一個很重要的因素,並且確實消除了我一直使用的那個詞——摩擦(friction),至少在 Medicare 端、政府支付方端是如此。自從導入以來,我們看到越來越多商業支付方開始將 ZYNRELEF 納入手術打包支付(bundle)之外,並在該 bundle 之外進行給付。我們在電話會議上提到的數字是:商業端估計覆蓋 1.10 億人。
And so kind of largely across the United States, very well covered for ZYNRELEF. There are pockets where we see ZYNRELEF still bundled, but certainly, we have the ability to go in and have those conversations at the payer level. And for the most part, they're willing to listen and make some changes for our patients.
因此,在美國範圍內,ZYNRELEF 的覆蓋相當完善。仍有一些區域我們看到 ZYNRELEF 依然被納入打包支付,但我們當然有能力在支付方層級介入並進行溝通。而且大多數情況下,他們願意傾聽,並為我們的病患做出一些調整。
And then as it relates to CrossLink, we allow them to select the accounts. And so by doing so, the natural selection gave us an expansion in that program, again, at 38%. And so the alignment between Heron and CrossLink now is almost 90% in terms of our focus. That's the highest it's ever been, significantly higher than the back half of 2025. And so what that really means is that we have a Heron employee in the account.
接著談到 CrossLink,我們讓他們來選擇客戶。因此,透過這樣的方式,自然的篩選使該計畫得以擴大——同樣是 38%。因此,目前 Heron 與 CrossLink 在聚焦方向上的對齊程度接近 90%。這是歷來最高,明顯高於 2025 年下半年。而這真正代表的是:在該客戶端有一位 Heron 的員工。
We have a CrossLink employee in that account. We have really good payer coverage in those accounts. That's why they were selected. And so those three pieces of the puzzle have shown us that, that's where we really have good success and are able to move ZYNRELEF forward. And so that gives us a lot of confidence for 2026.
在該客戶端也有一位 CrossLink 的員工。在這些客戶中,我們也有非常好的支付方覆蓋。這也是它們被選中的原因。因此,這三個拼圖要素讓我們看到:那正是我們能取得良好成效、並能推動 ZYNRELEF 向前發展的地方。因此,這也讓我們對 2026 年充滿信心。
Operator
Operator
(Operator Instructions) I would now like to turn the conference back to Craig Collard for closing remarks.
(Operator Instructions) 我現在要把電話會議交回給 Craig Collard 作結語。
Craig Collard - Chief Executive Officer, Director
Craig Collard - Chief Executive Officer, Director
Thank you, operator. I just want to thank everyone for joining the call today, and we look forward to speaking to you all next quarter.
謝謝,接線員。我只想感謝各位今天參與本次電話會議,我們期待在下個季度再與各位交流。
Operator
Operator
And this concludes today's program. Thank you for participating. You may now disconnect.
今天的節目到此結束。感謝各位參與。您現在可以掛線。